Other transfer or payment: SIF Stream2- Growth
Providence Therapeutics Holdings Inc.
$49,900,000.00
Enhancing Canadian Innovation in Biomanufacturing and R&D in mRNA Medicines
EF 2024-25 · 2024-05-23
Résumé
Enhancing Canadian Innovation in Biomanufacturing and R&D in mRNA Medicines
Programme
SIF Stream2- Growth
Bénéficiaire
Emplacement
Calgary, Alberta, Canada
Type de bénéficiaire
For-profit organization
Numéro d'entreprise
738045079
Type
Other transfer or payment
Source
Proactive Disclosure - Grants and Contributions
Tel que publié
Additional Information
Agreement Type is PRC, 2022/23 to 2026/27,
Additional Information (French)
Agreement Type is PRC, 2022/23 à 2026/27,
Agreement End Date
2044-01-01
Agreement Number
819773
Agreement Start Date
2024-05-23
Agreement Title
Enhancing Canadian Innovation in Biomanufacturing and R&D in mRNA Medicines
Agreement Title (French)
Renforcer l'innovation canadienne dans la biomanufacturation et la R&D des médicaments à ARNm
Agreement Type
Other transfer payment
Agreement Value
$49,900,000.00
Amendment Number
0
Description
Enhancing Canadian Innovation in Biomanufacturing and R&D in mRNA Medicines
Description (French)
Enhancing Canadian Innovation in Biomanufacturing and R&D in mRNA Medicines
Federal Riding
Calgary Midnapore
Federal Riding (French)
Calgary Midnapore
Federal Riding Number
48008
NAICS Code
339900
Organization Code
ic
Organization
Innovation, Science and Economic Development Canada | Innovation, Sciences et Développement économique Canada
Program Name
SIF Stream2- Growth
Program Name (French)
FIS Volet 2- Croissance
Program Purpose
-Encourage R&D that will accelerate technology transfer and commercialization of innovative products, processes and services;-Facilitate the growth and expansion of firms in Canada;-Attract and retain large scale investments to Canada; and-Advance industrial research, development and technology demonstration through collaboration between academia, non-profit organizations and the private sector.
Program Purpose (French)
-favoriser les activités de R-D qui accéléreront le transfert de la technologie et la commercialisation de produits, de processus et de services novateurs ;-faciliter la croissance et l'expansion des entreprises au Canada ;-attirer et conserver des investissements de grande envergure au Canada ; et-faire progresser la recherche industrielle, le développement et la démonstration de technologies grâce à la collaboration entre les universitaires, les organisations à but non lucratif et le secteur privé.
Recipient Business Number
738045079
Recipient City
Calgary
Recipient Country
CA
Recipient Legal Name
Providence Therapeutics Holdings Inc.
Recipient Operating Name
Providence Therapeutics Holdings Inc.
Recipient Postal Code
T2J3J1
Recipient Province or Territory
AB
Recipient Type
F
Reference Number
033-2024-2025-Q1-819773
